The Pharmaceutical Benefits Advisory Committee last month rejected the second application by Danish pharmaceutical giant Novo Nordisk to add Wegovy which is made from semaglutide to the Pharmaceutical Benefits Scheme as a treatment for severe obesity
2024;2:luae156
* Correspondence: Xianghong Huang, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Description Reviews (0) Description Description AOD 9604 (6mg) is a peptide fragment of human growth hormone (HGH) studied for its role in fat metabolism
For Wegovy and Ozempic , Novo Nordisks self-pay program through NovoCare Pharmacy can offer lower monthly costs than standard retail pricing, but they come with specific requirements
As previously mentioned, there is an oral form of semaglutide available, but it does tend to be more expensive than the injectable forms